HBC January 2017 News Bulletin

Tuesday, January 24, 2017

Looking ahead…looking ahead

  1. Travel Reimbursement Requests:airplane 

On January 9, 2017, an announcement to all staff and faculty was issued from the comptroller’s office indicating that the 60-day limit travel reimbursement policy will be enforced starting March 1, 2017 for travel that ended December 31, 2016 or later.  Therefore, make sure to submit any travel expense receipts within 60 days of your return to avoid having your travel reimbursement treated as a taxable fringe benefit.

  1. 2) H-1B policy change:H-1B 

Please note that KU recently changed its policy concerning H-1B visa applications.  The standard H-1B applications filed by the International Program Office are now for a three-year stay period rather than for a one-year stay period with yearly extensions.  This change was implemented because it currently takes nearly a year to obtain an H-1B visa (12+ weeks for the U.S. Dept. of Labor wage determinations and 8+ months for the USCIS to process the H-1B application).  Therefore, the process of obtaining an H-1B had to start nearly a year in advance to be completed on time and had to re-start almost immediately again to obtain an extension for the following year.  This put undue burden on the KU International Program Office and made it nearly impossible for the beneficiary to travel outside the U.S. as they were not allowed to travel while their case was being reviewed.  One disadvantage to this new policy is if an employer chooses to end the visa holder’s employment before the three-year approved visa ends, that employer must pay for the employee’s return transportation costs home.   However, this cost is offset by not paying the yearly H-1B extension application fee, which increased in December 2016.

 

NIH processes modification for 2017

  1. Final RPPR replaces FPR

As of January 1, 2017, NIH has retired and will no longer accept the Final Progress Report (FPR) old format (NOT-OD-17-022).  The FPR will be replaced by a new report, the Final Research Performance Progress Report (Final RPPR or F-RPPR), which has a format similar to the current annual\interim RPPR.  This step was taken as part of the federal government transition to standard reporting for all federally funded research awards or research related activities.  The final step of this transition, which is currently under consideration, will be a modification of the final reporting process for those who seek a competing renewal.  A notice will be issued in the near future to indicate when this last step will take effect and how it will work.

  1. Update to NIH Application Guide

An update to the NIH Application Guide, issued at the end of last year, will affect all award applications submitted on or after January 25, 2017.  Two important changes are to be kept in mind:

  1.  Only specific materials may be included in the appendix section of the proposal (NOT-OD-16-129) unless specified otherwise in the Funding Opportunity Announcement (FOA).  Applications submitted with appendix materials other than those listed below will be withdrawn and not reviewed.  The allowed materials for all applications are:
  • Blank informed consent/assent forms
  • Blank surveys, questionnaires, data collection instruments
  • FOA specified items: applications submitted without those appendix materials will be considered incomplete and will not be reviewed.

For applications proposing clinical trials:

  • Clinical trial protocols
  • Investigator’s brochure from Investigational New Drug as appropriate.
  1. The allowable post-submission materials that can be submitted due to unforeseen events after submission but prior to initial review has been simplified.  To review the list please refer to NIH Guide Notice NOT-OD-16-130

 

HBC 2017 Sciences Talks reminder

The HBC invites you to attend the HBC Science Talks held on February 17, 2017, at 1:30 pm in the Simons Auditorium.  For those who wish to share their research by participating in the afternoon poster session, please submit your abstract by 8:00 am on February 14 using our online form.



Grant Submission Important Deadlines

No Date Yet
DoD Breast Cancer Program Fiscal year 2017 - pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

May 17, 2017
NIH standard deadline for the Maximizing Investigators' Research Award (R35) – new, renewal, resubmission, revision.

May 25, 2017
NIH standard deadline for all Program Project Grants and Center Grants (P series) – new, renewal, resubmission, revision.

May 25, 2017
NIH standard deadline for all Institutional National Research Service Awards and Other Training Grants (T & D series) – new, renewal, resubmission, revision.

June 5, 2017
NIH Standard deadline for new R01 and U01 grant applications.

June 12, 2017
NIH Standard deadline for K series – new grant applications.

June 16, 2017
NIH Standard deadline for R03, R21, R33, R21/R33, R34, R36, UH2, UH3, UH2/UH3 – new grant applications.

July 5, 2017
NIH Standard deadline for R01 and U01 – renewals, resubmissions and revisions.

July 12, 2017
NIH Standard deadline for K series grants – renewals, resubmissions and revisions.

July 16, 2017
NIH Standard deadline for R03, R21, R33, R21/R33, R34, R36, UH2, UH3, UH2/UH3 – renewals, resubmissions and revisions.

July 19, 2017
NSF Faculty Early Career Development Program (CAREER) BIO, CISE, HER (17-050).

Recent Awards

Brian Blagg, Professor, Department of Medicinal Chemistry, was awarded $1,392,045 by the NIH - National Institutes of Health for his project entitled: “Optimization and Investigation of Cruentaren A analogs.”

Scott Hefty, Associate Professor, Department of Molecular Biosciences, was awarded $117,099 by the University of Washington for his project entitled: “Functional Genomics for Chlamydia.”

Blake Peterson, Regents Distinguished Professor, Medicinal Chemistry Department, was awarded $1,493,527 by the NIH - National Institutes of Health for his project entitled: “Synthetic Lethal Targeting of Growth Factor Receptors.”

Liang Xu, Professor, Department of Molecular Biosciences, was awarded $70,200 by the Thomas Jefferson University for his project entitled: “Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer.”

One of 34 U.S. public institutions in the prestigious Association of American Universities
Nearly $290 million in financial aid annually
44 nationally ranked graduate programs.
—U.S. News & World Report
Top 50 nationwide for size of library collection.
—ALA
23rd nationwide for service to veterans —"Best for Vets," Military Times
KU Today